SCHEMBL17047463

SCHEMBL17047463

Cc1ccccc1-c1ccc2ncnc(Nc3ccc(CC#N)cc3)c2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 11/20 0.77
▸ PIK3CA P42336 10/20 0.77
▸ PIK3CD O00329 3/20 0.71
▸ PIK3CB P42338 2/20 0.68
▸ CYP3A4 P08684 9/20 0.61
▸ CYP2D6 P10635 9/20 0.61
▸ TSHR P16473 9/20 0.61
▸ CYP2C19 P33261 9/20 0.61
▸ CLK4 Q9HAZ1 9/20 0.61
▸ CYP1A2 P05177 8/20 0.61
▸ USP2 O75604 5/20 0.55
▸ LMNA P02545 4/20 0.55
▸ ALDH1A1 P00352 6/20 0.55
▸ MAPK1 P28482 4/20 0.55
▸ HSD17B10 Q99714 3/20 0.55
▸ ALOX15 P16050 2/20 0.55
▸ CYP2C9 P11712 4/20 0.54
▸ TP53 P04637 1/20 0.54
▸ HIF1A Q16665 1/20 0.53
▸ APEX1 P27695 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17047554 0.87 PIK3CG (1.00) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047521 0.87 PIK3CG (1.00) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL18382198 0.86 PIK3CG (0.81) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047432 0.85 PIK3CG (0.74) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047482 0.84 PIK3CG (0.82) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047570 0.84 PIK3CG (0.84) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL18382156 0.83 MAPKAPK2 (0.58) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047462 0.83 PIK3CG (1.00) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047469 0.82 PIK3CG (0.69) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4
SCHEMBL17047520 0.81 PIK3CG (0.67) PIK3CGPIK3CAPIK3CDPIK3CBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202374-B2 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-02-12 — — US disclosed
US-10202374-B2 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-02-12 — — US disclosed
EP-3110801-B1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2019-01-30 — — EP disclosed
EP-3110801-B1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2019-01-30 — — EP disclosed
US-20170015662-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-01-19 — — US disclosed
US-20170015662-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-01-19 — — US disclosed
US-20170015662-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-01-19 — — US disclosed
EP-3110801-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-01-04 — — EP disclosed
WO-2015128873-A1 \"6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS\ COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-09-03 — — WO disclosed
WO-2015128873-A1 \"6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS\ COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202374-B2 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors PIK3CA, PI4KA, PDPK1 PIK3CG 5/4885PIK3CA 1/4885PIK3CD 4/4885
US-20170015662-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS PIK3CA, PI4KA, PDPK1 PIK3CG 5/4885PIK3CA 1/4885PIK3CD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback